Expression of SLC5A5 in Circulating Tumor Cells May Distinguish Follicular Thyroid Carcinomas from Adenomas: Implications for Blood-Based Preoperative Diagnosis.
Hyeon-Gun JeeByoung-Ae KimMinjun KimHyeong Won YuJune Young ChoiSu-Jin KimKyu Eun LeePublished in: Journal of clinical medicine (2019)
Preoperative diagnosis of thyroid nodules reduces unnecessary surgery. Circulating tumor cells (CTCs) may contain information of primary tumor(s). We asked whether the peripheral blood expression of genes specific for circulating tumor cells (CTCs) differentiates benign thyroid nodules from malignant nodules. Peripheral blood mononuclear cells from thyroid nodule patients (n = 20) were isolated preoperatively and the expression of seven CTC-associated genes was measured in patients with thyroid nodule(s) (n = 20). Among the tested genes, the expression of SLC5A5 and LGALS3 were validated in a larger number of patients (n = 64) and our results show that SLC5A5 expression differentiated follicular adenomas from follicular carcinomas (area under the curve (AUC) = 0.831). The expression of SLC5A5 in CTCs may preoperatively distinguish thyroid follicular adenomas from follicular carcinomas.
Keyphrases
- circulating tumor cells
- poor prognosis
- end stage renal disease
- circulating tumor
- ejection fraction
- binding protein
- long non coding rna
- chronic kidney disease
- high grade
- minimally invasive
- peritoneal dialysis
- patients undergoing
- prognostic factors
- gene expression
- atrial fibrillation
- social media
- percutaneous coronary intervention